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Abstract 
Background: Previous study showed that downregulated BCL11B expression in T cell acute lymphoblastic leukemia 
(T-ALL) cell line Molt-4 inhibited cell proliferation and induce apoptosis, which may be related to PHTF1 gene overex-
pression. The objective of this study was to investigate the expression of PHTF1 and related genes in ALL and further 
explore its function in T-ALL cell lines.
Methods: Real-time PCR was used to determine the gene expression level of PHTF1 in hematologic malignancies. 
The PHTF1, BCL11B, FEM1B and Apaf-1 gene expression levels and correlations were analyzed in patients with primary 
ALL (including T-ALL and B-ALL) and healthy individuals (HIs). Inhibition and overexpression of PHTF1 by lentiviral 
transduction were performed using the Molt-4 and Jurkat cell lines. Cell growth and apoptosis were measured by the 
Cell Counting Kit-8 assay and flow cytometry, respectively. Upon PHTF1 overexpression, the BCL11B, FEM1B and Apaf-1 
gene expression levels were determined by real-time PCR.
Results: PHTF1 overexpression was found in both T-ALL (p = 0.004) and B-ALL (p < 0.001) groups compared with HIs 
group. A trend toward a negative correlation between the PHTF1 and BCL11B genes was detected for the T-ALL group, 
while positively correlated expression was found for the PHTF1 and BCL11B genes in HIs (P = 0.001). FEM1b and Apaf-1 
overexpression was found in recently diagnosed ALL patients compared with HIs (p < 0.05). Positively correlated 
expression was found for the PHTF1, FEM1b and Apaf-1 genes in patients with ALL (p < 0.05) and HIs (p < 0.05). Direct 
up-regulation of PHTF1 expression inhibited the proliferation of Jurkat and Molt-4 cells and effectively induced apop-
tosis in Molt-4 cells. Direct inhibition of PHTF1 expression had no significant effect on the proliferation or apoptosis of 
Jurkat and Molt-4 cells. FEM1b and Apaf-1 overexpression, which did not obviously alter the BCL11B expression level, 
was detected in PHTF1-transduced T-ALL cell lines.
Conclusions: PHTF1 overexpression is responsible for regulating cell proliferation and apoptosis in T-ALL cell lines. 
PHTF1 may be a tumor-suppressor like gene and a therapeutic target for triggering the PHTF1-FEM1b-Apaf-1 apoptosis 
pathway.
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Background
T cell acute lymphoblastic leukemia (T-ALL) results from 
clonal malignant T cell proliferation, is an aggressive 
malignancy that does not respond well to chemotherapy 
and has a poorer prognosis [1, 2]. The cellular biology 
and pathogenesis of T-ALL are relatively complex, and 
these might be related to the different original malignant 
T cell clone [3–5]. Complex acquired genetic aberrations 
include chromosomal translocations, gene rearrange-
ments and mutations, resulting in the abnormal expres-
sion of oncogenes such as Notch1, TAL1 (T-cell acute 
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lymphoblastic leukemia 1), and BCL11B (B-cell chronic 
lymphocytic leukemia/lymphoma 11B), which may be 
associated with advanced disease and resistance to treat-
ment [6–10].
The B-cell leukemia/lymphoma 11B (BCL11B) gene 
is a member of the BCL family and plays a crucial role 
in the development, proliferation, differentiation, and 
subsequent survival of T cells [11]. BCL11B gene altera-
tions are related to the malignant T cell transformation 
that occurs in hematological malignancies [6, 12–15]. 
Remarkably, the BCL11B gene is responsible for regu-
lating apoptosis and cell proliferation [16–18]. Previous 
studies [16–18] have shown that inhibition of BCL11B 
expression by siRNA selectively inhibits proliferation and 
effectively induces apoptosis in T-ALL cell lines (Jurkat 
and Molt-4) but not in normal mature T and CD34+ 
cells [17, 19]. Additionally, global gene expression profil-
ing has revealed that BCL11B siRNA-mediated apoptosis 
in Molt-4 cells might be related to the PHTF1 gene [10].
PHTF1 (putative homeodomain transcriptional fac-
tor) is a putative homeobox gene located at 1p11-p13 in 
the human genome [20]. This gene is evolutionarily con-
served [21] and mainly expressed in the testis [20]. As a 
transcription factor, the PHTF1 gene is mainly involved 
in biological processes such as DNA- dependent tran-
scription and the regulation of biological processes. 
However, studies on the PHTF1 gene in leukemia have 
not been reported. FEM1b (feminization-1 homolog b) 
has been identified as a binding partner for PHTF1 [22]. 
Previous in vitro experiments have suggested that human 
FEM1b is involved in apoptosis. FEM1b is a proapop-
totic protein that interacts with the apoptosis-inducing 
proteins Fas, tumor necrosis factor receptor-1 (TNFR1), 
and apoptotic protease activating factor-1 (Apaf-1) [23]. 
Therefore, we hypothesized that the BCL11B gene and 
the PHTF1-FEM1b-Apaf-1 pathway may work together 
in tumor cell apoptosis. In this study, we analyzed the 
expression level of PHTF1 and its related genes for the 
first time in patients with ALL. To further explore its 
function in T-ALL cell lines, we performed experiments 
involving the down regulation or overexpression of 
PHTF1 in T-ALL cell lines using growth and apoptosis 
assays in vitro.
Results
Expression characteristics and correlation analysis of the 
PHTF1 and BCL11B genes in T‑ALL and B‑ALL patients 
and HIs
In order to characterize the expression of PHTF1 in pri-
mary T-ALL samples, we detected the expression level of 
PHTF1 in peripheral blood mononuclear cells (PBMCs) 
from 9 cases with T-ALL (median: 2.73  %, mean rank: 
20.33, P = 0.004), as well as 13 cases with B-ALL (median: 
3.34 %, mean rank: 21.54, P < 0.001). Overexpression of 
PHTF1 was found in both groups in comparison with HIs 
group, and there was no significant difference between 
the two ALL subtypes (Fig. 1a).
As previously reported [24], the BCL11B mRNA 
expression level in PBMCs from patients with T-ALL 
(median: 389.04 copies/105 β2M copies, mean rank: 
26.56, P  <  0.001) was significantly higher than that in 
patients with B-ALL (median: 30.39 copies/105 β2M cop-
ies, mean rank: 7.69) (Fig. 1b).
Spearman’s rank correlation analysis of the expression 
levels of the PHTF1 and BCL11B genes was performed 
for patients with T-ALL and B-ALL. No significant corre-
lation was found for the PHTF1 and BCL11B genes in the 
Fig. 1 PHTF1 and BCL11B expression level in the different ALL 
subtypes and healthy individuals. a PHTF1 expression level in the 
different ALL subtypes and healthy individuals. PHTF1 overexpres-
sion was detected in recently diagnosed T-ALL and B-ALL patients. 
P = 0.004 for T-ALL versus HIs, P < 0.001 for B-ALL versus HIs. b BCL11B 
expression level in the different ALL subtypes and healthy individuals. 
BCL11B overexpression was detected in patients with T-ALL. P < 0.001 
for T-ALL versus B-ALL
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B-ALL patients (rs = 0.044, P = 0.887) (Fig. 2a). However, 
a negative correlation trend was detected for the PHTF1 
and BCL11B genes in the T-ALL patient (rs  =  −0.083, 
P  =  0.831) (Fig.  2b). A positively correlated expression 
level for the PHTF1 and BCL11B genes was found in the 
HIs (rs = 0.891, P = 0.001) (Fig. 2c).
Overexpression characteristics and positive correlation 
of the PHTF1, FEM1b and Apaf‑1 genes in ALL patients 
and HIs
FEM1b and Apaf-1 overexpression was found in recently 
diagnosed ALL (FEM1b median: 11.19  %, mean rank: 
15.90, P  =  0.014) (Apaf-1 median: 7.47  %, mean rank: 
16.87, P  =  0.001) patients compared with HIs (FEM1b 
median: 4.31 %, mean rank: 8.65) (Apaf-1 median: 2.52 %, 
mean rank: 7.20) (Fig. 3).
Positively correlated expression for the PHTF1, FEM1b 
and Apaf-1 genes was found in ALL patients (PHTF1 
vs. FEM1b: rs =  0.864, P  <  0.001 and FEM1b vs. Apaf-
1: rs  =  0.682, P  =  0.005) (Fig.  4a, b) and HIs (PHTF1 
vs. FEM1b: rs = 0.939, P < 0.001 and FEM1b vs. Apaf-1 
rs = 0.830 P = 0.003) (Fig. 4c, d).
Inhibition or overexpression of PHTF1 by lentiviral 
transduction in T‑ALL cell lines
To investigate the potential role of PHTF1 in leukemo-
genesis, we first transfected Jurkat and Molt-4 cells with 
an active shRNA pair. We found that the PHTF1 expres-
sion level in Jurkat (Fig. 5a) and Molt-4 (Fig. 5b) cells was 
downregulated approximately 3-fold compared with a 
scrambled lentiviral transduction control group (CON 1).
Similarly, we transduced Jurkat and molt-4 cells using 
a lentivirus expressing the PHTF1 gene. The PHTF1 
expression level was approximately 2291-fold (Jurkat) 
(Fig.  5c) and approximately 1100-fold (Molt-4) (Fig.  5d) 
higher compared with the lentiviral transduction control 
group (CON 2).
PHTF1 overexpression inhibits the proliferation of Jurkat 
and Molt‑4 cells
The effect of PHTF1 on Jurkat and Molt-4 cell growth 
was next evaluated. Compared with the negative control 
group, PHTF1 had markedly lower proliferation in both 
Jurkat (n = 3, P = 0.004) (Fig. 6a) and Molt-4 cells (n = 3, 
P = 0.007) (Fig. 6b). However, we found no obvious pro-
liferation inhibition after PHTF1 knockdown in Jurkat 
(Fig. 6c) and Molt-4 cells (Fig. 6d).
PHTF1 overexpression remarkably induces apoptosis 
in Molt‑4 cells
We then explored the effects of PHTF1 overexpres-
sion on T-ALL apoptosis in in vitro assays. The ratio of 
Fig. 2 Correlation analyses of the PHTF1 and BCL11B expression lev-
els. a No significant correlation was found for the PHTF1 and BCL11B 
genes in B-ALL patients. b A negative correlation trend was detected 
for the PHTF1 and BCL11B genes in the T-ALL patients. c A positively 
correlated expression level for the PHTF1 and BCL11B genes was 
found in the HIs
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apoptosis in Molt-4 cells was 78.67 ± 29.26 %, and it was 
15.50  ±  5.97  % for the negative control group (n  =  3, 
P = 0.021) (Fig. 7a). Interestingly, the apoptosis ratio for 
Jurkat cells was 15.87 ± 5.65 %, while it was 9.57 ± 2.35 % 
for the negative control group. No significant difference 
between these two groups was found (n = 3, P = 0.150) 
(Fig.  7b). Notably, we could observe an increase in the 
trend toward apoptosis for Jurkat cells after PHTF1 
upregulation; however, we found no significant apopto-
sis after PHTF1 knockdown in the Jurkat (Fig.  7c) and 
Molt-4 cells (Fig. 7d).
PHTF1‑related gene expression in Jurkat and Molt‑4 
overexpressing cells
To further examine the mechanism by which PHTF1 
regulates apoptosis, we investigated the expression of 
PHTF1-related genes in PHTF1 (PHTF1) or control 
(CON 2) infected Jurkat and Molt-4 cells. In infected Jur-
kat cells, the BCL11B expression level was unchanged, 
while FEM1b and Apaf-1 were upregulated approxi-
mately 2.4- and 4.4-fold, respectively (Fig.  8a). In trans-
fected Molt-4 cells, the BCL11B expression level was also 
unchanged, while FEM1b and Apaf-1 were upregulated 
approximately 6.3- and 29.4-fold, respectively (Fig. 8b).
Discussion
Despite significant improvement in our understand-
ing of T-ALL biology and pathogenesis [25], knowledge 
of the T cell activative signaling pathways involved in 
T-ALL remains limited. Thus, novel molecular insights 
and therapeutic approaches are urgently needed. Thus, 
based on previous finding that BCL11B siRNA-mediated 
apoptosis in the Molt-4 T-ALL cell line might be related 
to the PHTF1 gene [10], we focused our attention on the 
characteristics of BCL11B and PHTF1 gene expression in 
T-ALL patients. We found a positive correlation between 
the PHTF1 and BCL11B genes in healthy individuals. In 
contrast, a trend toward a negative correlation was found 
for the PHTF1 and BCL11B genes in the T-ALL patient 
although there was no statistical significance, which may 
be due to the limited number of samples. However, this 
result may indicate that there are different expression 
patterns for both of these genes in T-ALL, and for further 
confirmation of the relationship between PHTF1 and 
BCL11B is needed in a larger cohort of T-ALL samples. 
Low BCL11B expression is associated with poor prog-
nosis, particularly in the standard risk group for thymic 
T-ALL [26]. PHTF1 and BCL11B genetic disorders may 
contribute to T-ALL pathogenesis.
To further explore its function in T-ALL cell lines, we 
downregulated and overexpressed PHTF1 in T-ALL cell 
lines and examined cell line growth and apoptosis using 
in vitro assays. PHTF1 up-regulation inhibits the prolif-
eration of Jurkat and Molt-4 cells and effectively induces 
apoptosis in Molt-4 cells. The BCL11B expression level 
was unchanged, while FEM1b and Apaf-1 were upregu-
lated. Interestingly, compared with the Jurkat cells, the 
remarkable apoptosis of Molt-4 cells may be related to 
the higher FEM1b and Apaf-1 expression level. Based 
on the reports regarding the expression characteristics 
of tumor suppressor genes in leukemia, such as wilms 
tumor 1 (WT1), which was consistently found to be 
highly expressed in peripheral blood (PB) or bone mar-
row (BM) in acute myeloid leukemia (AML) and is used 
for inhibiting tumor targeting [27], we hypothesized 
that PHTF1 is involved in negative regulation of tumor 
growth. Therefore, we considered that PHTF1 has tumor-
suppressive activity and triggers the PHTF1-FEM1b-
Apaf-1 apoptosis pathway using in vitro assays. However, 
direct inhibition of PHTF1 expression, and the BCL11B 
expression level was unchanged (data not shown), had 
no significant effect on the proliferation or apoptosis of 
Jurkat and Molt-4 cells. Therefore, we considered that 
PHTF1 might be the downstream gene of the BCL11B.
In order to further characterize the role of PHTF1 in 
T-ALL, it is of interest to analyze the downstream genes 
regulated by PHTF1. Because overexpression of PHTF1 
was found in both groups (T-ALL and B-ALL) in com-
parison with HIs group, we characterized the expres-
sion of FEM1b and Apaf-1, which are mainly involved in 
apoptosis in ALL patients and HIs. In a previous study 
[22], western blotting and immunofluorescence assays 
revealed the presence of PHTF1 and FEM1b in the same 
cells, and association between these proteins was dem-
onstrated by co-immunoprecipitation. Previous in  vitro 
Fig. 3 FEM1b and Apaf-1 expression levels in the ALL patients and 
healthy individuals. FEM1b and Apaf-1 overexpression was found 
in recently diagnosed ALL patients versus HIs. P = 0.014 for FEM1b, 
P = 0.001 for Apaf-1
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experiments have suggested that the human FEM1b gene 
is involved in apoptosis. Human FEM1b is 99  % identi-
cal to the mouse protein, and it is reportedly capable of 
associating with the intracellular tail of the death mem-
brane receptors Tnfrsf6 (tumor necrosis factor receptor 
superfamily, member 6; also known as Fas) and Tnfrsf1a 
(also known as TNFR1) [28]. Proteasome inhibitor treat-
ment of SW620, HCT-116, and DLD-1 cells led to upreg-
ulation of the FEM1b protein and was associated with 
apoptosis induction. Blockade of FEM1b upregulation 
with morpholino antisense oligonucleotides suppressed 
proteasome inhibitor-induced apoptosis in these cells. 
The authors of this study have demonstrated that FEM1b 
can induce apoptosis when overexpressed in some cell 
lines. The proapoptotic protein FEM1b could repre-
sent a novel molecular target for overcoming apoptosis 
resistance in colon cancer therapy [29]. As a binding pro-
tein for FEM1b, Apaf-1 is a central component of the 
intrinsic apoptosis pathway. High Apaf-1 expression ele-
vates erythroid apoptosis in iron overload myelodys-
plastic syndrome [30]. Zermati et al. have suggested that 
Apaf-1 deficiency contributes to tumor progression not 
only by decreasing activation of the apoptotic caspase 
but also by reducing DNA damage-induced cell cycle 
arrest, thus weakening the cytostatic effects of chemo-
therapy and radiotherapy [31]. FEM1b and Apaf-1 over-
expression was found in samples from patients recently 
diagnosed with ALL, and a positively correlated expres-
sion level for the PHTF1, FEM1b and Apaf-1 genes was 
found in ALL patients and HIs. Thus, PHTF1, FEM1b, 
and Apaf-1 might be involved in the same apoptosis 
pathway. The data provide the first molecular biological 
Fig. 4 Correlation analysis of the PHTF1, FEM1b and Apaf-1 expression levels. Positively correlated expression for the PHTF1, FEM1b and Apaf-1 genes 
was found in ALL patients (a PHTF1 vs. FEM1b, b FEM1b vs. Apaf-1) and HIs (c PHTF1 vs. FEM1b, d FEM1b vs. Apaf-1)
Page 6 of 11Huang et al. Cancer Cell Int  (2015) 15:93 
characterization of these genes at the gene expression 
level. To further explore its function in B-ALL,further 
studies will be performed to address this question.
Conclusions
In conclusion, PHTF1 overexpression is responsible for 
regulating the cell proliferation and apoptosis of T-ALL 
cell lines. Based on these preliminary findings, and reports 
regarding the expression characteristics of tumor sup-
pressor genes in leukemia, such as wilms tumor 1 (WT1), 
which was consistently found to be highly expressed 
in peripheral blood (PB) or bone marrow (BM) in acute 
myeloid leukemia (AML) and is used for inhibiting tumor 
targeting, we hypothesized that PHTF1 is involved in 
negative regulation of tumor growth. PHTF1 may be a 
tumor-suppressor like gene and a therapeutic target for 
triggering the PHTF1-FEM1b-Apaf-1 apoptosis pathway.
Methods
Samples
Nine newly diagnosed and untreated patients with 
T-ALL, and thirteen newly diagnosed and untreated 
patients with B-ALL were recruited. The diagnoses for all 
patients were based on cytomorphology, immunohisto-
chemistry, cytoimmunological and cytogenetic analysis. 
Peripheral blood mononuclear cells (PBMCs) from ten 
healthy individuals (HIs) served as controls. The details 
of the samples are listed in Table  1. Peripheral blood 
was collected by heparin anticoagulation, and PBMCs 
were separated using the Ficoll-Hypaque gradient cen-
trifugation method. All procedures were conducted in 
accordance with the guidelines of the Medical Ethics 
committees of the Health Bureau of Guangdong Prov-
ince, China.
Fig. 5 Knockdown and overexpression of PHTF1 in T-ALL cell lines. a, b PHTF1 knockdown with PHTF1 shRNA lentivirus in Jurkat (a) and Molt-4 (b) 
cells. PHTF1 was down-regulated approximately 3-fold in both Jurkat and Molt4 cells. P < 0.01 for bar 1 versus bar 2 and bar 3 versus bar 4. c, d PHTF1 
overexpression by PHTF1 lentivirus in Jurkat (c) and Molt-4 (d) cells. PHTF1 was up-regulated approximately 2291-fold in Jurkat cells and approxi-
mately 1100-fold in Molt4 cells. P < 0.05 for bar 1 versus bar 2 and bar 3 versus bar 4. The results represent the mean ± SEM (n = 3)
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Cell culture
Cells from the well-characterized human T-cell acute 
lymphoblastic leukemia (T-ALL) cell lines Jurkat and 
Molt-4 were obtained from American Type Culture Col-
lection (ATCC, Manassas, Virginia, USA) and maintained 
in RPMI-1640 media (Gibco, New York, USA) containing 
10 % fetal bovine serum (FBS, NATOCOR, Argentina) at 
37 °C and 5 % CO2.
Lentivirus production and transduction
Two recombinant lentivirus vectors based on the 
U6-shRNA-Ubi-EGFP and U6-NC-Ubi-EGFP vec-
tors (purchased from Shanghai GeneChem Co., Ltd) 
were constructed to target the human PHTF1 gene 
(NM_006608) and as a scrambled negative control, 
respectively. The target sequence of the PHTF1 shRNA 
was ACCTAAACTCTCAGGTAAA, and that for the neg-
ative control was TTCTCCGAACGTGTCACGT.
Two recombinant lentivirus vectors based on the Ubi-
PHTF1-3FLAG-SV40-EGFP and Ubi-3FLAG-SV40-
EGFP vectors (purchased from Shanghai GeneChem Co., 
Ltd) were constructed to express the human PHTF1 gene 
(NM_006608) and green fluorescence protein gene (neg-
ative control), respectively.
The transduced cells were divided into four groups: 
shRNA transduction (RNAi), scrambled control (CON 1), 
Fig. 6 PHTF1 overexpression inhibits the proliferation of Jurkat and Molt-4 cells. a Jurkat cells infected with PHTF1 (PHTF1) or control (CON 2) 
lentivirus were seeded in a 96-well plate and incubated for 72 h. The CCK8 assay demonstrated that cells infected with PHTF1 have lower viability 
compared with control. The results shown are the mean ± SEM (n = 3). P = 0.004 for bar 1 versus bar 2. b Molt-4 cells infected with PHTF1 (PHTF1) 
or control (CON 2) lentivirus were seeded in a 96-well plate and incubated for 72 h. The CCK8 assay demonstrated that cells infected with PHTF1 
have lower viability compared with controls. The results represent the mean ± SEM (n = 3). P = 0.007 for bar 1 versus bar 2. c Jurkat cells infected 
with PHTF1 shRNA (RNAi) or control (CON 1) lentivirus were seeded in a 96-well plate and incubated for 72 h. The CCK8 assay demonstrated that 
cells infected with PHTF1 shRNA have no significant difference compared with controls. The results represent the mean ± SEM (n = 3). NS no 
significance. d Molt4 cells infected with PHTF1 shRNA (RNAi) or control (CON 1) lentivirus were seeded in a 96-well plate and incubated for 72 h. The 
CCK8 assay demonstrated that cells infected with PHTF1-shRNA have no significant difference compared with controls. The results represent the 
mean ± SEM (n = 3). NS no significance
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PHTF1 gene transduction (PHTF1), and transduction con-
trol (CON 2). The lentiviral titers ranged from 1 to 2 × 108 
TU/mL. Transduction was performed by ‘spin-infection’, 
and cells and lentiviruses (MOI = 5 for Jurkat, MOI = 10 
for molt4) plus 10 μg/mL polybrene were mixed and spun 
at 900 × g for 40 min. The transfected cells were then cul-
tured for 2–3 days prior to analysis by flow cytometry. For 
GFP cell analysis, GFP+ cells were cultured for 3 days and 
then FACS purified using the Aria II System (Becton–Dick-
inson Immunocytometry Systems, San Jose, CA, USA).
RNA extraction and cDNA synthesis
RNA was extracted using the TRIzol kit (Invitrogen, 
Carlsbad, CA, USA), and it was then reverse-transcribed 
Fig. 7 PHTF1 overexpression induces apoptosis in Molt-4 cells. a Representative FACS plots and summary (right) of apoptotic Molt 4 cells after 
transduction with PHTF1 (PHTF1, left) or control (CON 2, middle) lentivirus. Data represent the mean ± SEM (n = 3). P = 0.021 for bar 1 versus bar 
2. b Representative FACS plots and summary (right) of apoptotic Jurkat cells after transduction with PHTF1 (PHTF1, left) or control (CON 2, middle) 
lentivirus. Data represent the mean ± SEM (n = 3). NS no significance. c, d Summary of apoptotic Jurkat (c) or Molt-4 (d) cells after transduction 
with PHTF1 shRNA (RNAi) or control (CON 1) lentivirus. Data represent the mean ± SEM (n = 3). NS no significance
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into first-strand cDNA using random hexamer primers 
and the reverse transcriptase Superscript II Kit (TaKaRa, 
Dalian, PR China) according to the manufacturer’s 
instructions.
Real‑time polymerase chain reaction
Real-time quantitative reverse transcription-polymerase 
chain reaction (qRT-PCR)quantitative detection of the 
β2 microglobulin (β2M), BCL11B, PHTF1, FEM1b, and 
Apaf-1 genes in cDNA from PBMCs was performed 
using TaqMan real-time PCR. To precisely determine the 
BCL11B copy number, a duplex vector, including a frag-
ment of the BCL11B and β2M genes was constructed 
and used as a reference (the duplex vector was a gift 
from Prof. C. A. Schmidt, Ernst-Moritz-Arndt Univer-
sity Greifswald, Germany). Another vector including the 
PHTF1, FEM1b, and Apaf-1 genes was constructed based 
on DNA concentration, and it was measured by spectro-
photometry and confirmed by quantitative gel electro-
phoresis. Standard dilutions of the vector ranging from 
107 to 101 copies were prepared.
Briefly, PCR was performed in a 25  μL total volume 
containing 2 μL cDNA, 25 pmol of each primer, 10 nmol 
of each dNTP, 1.5 U AmpliTaq Gold (Applied Biosys-
tems, Branchburg, NJ, USA), 5  pmol 6FAM-TAMRA 
probe, and PCR buffer containing 4.5 mM MgCl2. After 
an initial denaturation at 95  °C for 5  min, 50 cycles of 
95 °C for 15 s and 64 °C for 1 min were performed.
Primers and probes for β2M, BCL11B, PHTF1, 
FEM1b, and Apaf-1 gene amplification were synthe-
sized by Invitrogen (Carlsbad, CA, USA) (Table  2). The 
absolute amounts of BCL11B and β2M were meas-
ured in two independent assays, and the BCL11B con-
tent per 100,000 β2M copies was calculated using 
the following formula: n  =  100,000  ×  BCL11B/β2M. 
The amounts of the PHTF1, FEM1b, and Apaf-1 cop-
ies were calculated using the following formulas: 
n = PHTF1/β2M ×  100  %, n = FEM1b/β2M ×  100  %, 
and n = Apaf-1/β2M × 100 %.
The absolute amounts of BCL11B and β2M were meas-
ured in two independent assays, and the BCL11B content 
per 100,000 β2M copies was calculated using the follow-
ing formula: n  =  100,000  × BCL11B/β2M [12]. In this 
study, we used this method to measure BCL11B expres-
sion. The standard for other genes (PHTF1, FEM1B and 
Apaf-1) was constructed using another triplex plasmid 
(synthesized by Invitrogen), and we determined the β2M, 
PHTF1, FEM1B and Apaf-1 copy number, which were 
compared relative to the gene expression level of the β2M 
reference gene between different clinical samples.
Cell proliferation assay
Cell proliferation was detected using the Cell Count-
ing Kit-8 (CCK-8) assay according to the manufacturer’s 
instructions. Briefly, Jurkat and Molt-4 cells transfected 
with or without lentiviruses at a density of 5  ×  105 
cells/mL were seeded into a 96-well plate (100 µL/well). 
CCK-8 reagent (10 µL) was then added to each well, and 
the cells were cultured for 3 h at 37 °C and 5 % CO2. After 
incubation, the absorption value (450  nm) of each well 
was measured with a 680-type microplate reader (Bio-
Rad, Berkeley, CA, USA).
Fig. 8 Genes activated with PHTF1 overexpression. a Expression 
level of BCL11B, FEM1b and Apaf-1 in Jurkat cells after PHTF1 over-
expression by transduction with PHTF1 lentivirus (PHTF1) or in the 
presence of control lentivirus (CON 2). The BCL11B expression level 
was unchanged versus control; FEM1b and Apaf-1 were up-regulated 
2.4- and 4.4-fold, respectively, versus control. Data shown are the 
mean ± SEM (n = 3), P = 0.007 for bar 3 versus bar 4; P = 0.009 for 
bar 5 versus bar 6. b Expression levels of BCL11B, FEM1b and Apaf-1 in 
Molt-4 cells after PHTF1 overexpression by PHTF1 lentivirus (PHTF1) 
or control lentivirus (CON 2). The BCL11B expression level was 
unchanged versus control; FEM1b and Apaf-1 were up-regulated 
6.3- and 29.4-fold, respectively, versus control. Data shown are the 
mean ± SEM (n = 3), P = 0.020 for bar 3 versus bar 4; P = 0.005 for 
bar 5 versus bar 6
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Apoptosis assays
Annexin-V binding assays were conducted 72  h after 
lentiviral transduction using the Apoptosis Detection 
Kit (eBioscience, San Diego, CA, USA) according to the 
manufacturer’s instructions. Briefly, cells were washed 
twice with PBS, resuspended in 100  μL binding buffer 
containing APC-conjugated Annexin V, and incubated 
in the dark for 15 min. Cells were then washed and sus-
pended in 200 μL binding buffer containing PI. Annexin 
V positive cells were analyzed with an Accuri C6 flow 
cytometer (Becton–Dickinson Immunocytometry Sys-
tems, San Jose, CA, USA).
Statistical analyses
Differences in mRNA expression between two clini-
cal groups were analyzed by the Mann–Whitney U test. 
Data are presented as medians. Spearman’s rank correla-
tion analysis was used to analyze the PHTF1, BCL11B, 
FEM1b, and Apaf-1 mRNA level in different clinical 
samples. An independent-sample t test was used for all 
comparisons, and data are represented as mean ± SD. P 
values <0.05 were considered statistically significant.
Abbreviations
ALL: acute lymphoblastic leukemia; Apaf-1: apoptotic protease activating 
factor-1; ATCC: American Type Culture Collection; B-ALL: B-cell acute lympho-
blastic leukemia; β2M: β2 microglobulin; BCL11B: B-cell leukemia/lymphoma 
11B; CCK8: Cell Counting Kit-8; FEM1b: feminization-1 homolog b; HIs: healthy 
individuals; PBMCs: peripheral blood mononuclear cells; PHTF1: putative 
homeodomain transcriptional factor; qRT-PCR: real-time quantitative reverse 
transcription-polymerase chain reaction; siRNA: small interference RNA; 
shRNA: small hairpin RNA; T-ALL: T-cell acute lymphoblastic leukemia; TNFR1: 
tumor necrosis factor receptor-1.
Authors’ contributions
XD, YQL and XH conceived of the study, participated in its design and coor-
dination and helped draft the manuscript. XH, SXG, LJZ, and XLW performed 
experiments and analyses. JYW, ZSL, MML and CXD were responsible for 
patient treatment and acquiring of clinical data. All authors read and approved 
the final manuscript.
Author details
1 Southern Medical University, 510515 Guangzhou, People’s Republic of China. 
2 Department of Haematology, Guangdong General Hospital, Guangdong 
Academy of Medical Sciences, 510080 Guangzhou, People’s Republic of China. 
3 Institute of Hematology, Medical College, Jinan University, 510632 Guang-
zhou, People’s Republic of China. 4 Key Laboratory for Regenerative Medicine 
of Ministry of Education, Jinan University, 510632 Guangzhou, People’s 
Republic of China. 
Acknowledgements
The project was sponsored by Grants from the National Natural Science 
Foundation of China (No. 81100384, No. 81270648, No. 91129720, and No. 
30771980). We thank Peng Li and Yiren Xiao who contributed essential 
materials for the in vitro studies. We thank Dr. Shannon T. Bailey who made 
significant language revisions.
Compliance with ethical guidelines
Competing interests
The authors declare that they have no competing interests.
Received: 24 February 2015   Accepted: 8 September 2015
References
 1. Aifantis I, Raetz E, Buonamici S. Molecular pathogenesis of T-cell leukae-
mia and lymphoma. Nat Rev Immunol. 2008;8:380–90.
 2. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J 
Med. 2004;350:1535–48.
 3. Zheng HT, Wang X, Ma Y, Xu B, Chen S, Yang LJ, Wu XL, Przybylski GK, 
Huang SM, Ye TZ, Li YQ. The TCR gammadelta repertoire and relative gene 
Table 1 The details of samples used in study
Diagnosis Subtype Numbers Age (year)
Total Male Female Range Median
ALL 22 17 5 15–55 22.5
T-ALL 9 7 2 17–27 20
B-ALL 13 10 3 15–55 24
HIs 10 6 4 22–35 25.5





















Page 11 of 11Huang et al. Cancer Cell Int  (2015) 15:93 
expression characteristics of T-ALL cases with biclonal malignant Vdelta1 
and Vdelta2 T cells. DNA Cell Biol. 2014;33:49–56.
 4. Gimenes-Teixeira HL, Lucena-Araujo AR, Dos Santos GA, Zanette DL, 
Scheucher PS, Oliveira LC, Dalmazzo LF, Silva-Junior WA, Falcao RP, Rego 
EM. Increased expression of miR-221 is associated with shorter overall 
survival in T-cell acute lymphoid leukemia. Exp Hematol Oncol. 2013;2:10.
 5. Chen S, Huang X, Zheng HT, Geng SX, Wu XL, Yang LJ, Weng JY, Du X, 
Li YQ. The evolution of malignant and reactive γδ+ T cell clones in a 
relapse T-ALL case after allogeneic stem cell transplantation. Mol Cancer. 
2013;12:73.
 6. Oshiro A, Tagawa H, Ohshima K, Karube K, Uike N, Tashiro Y, Utsunomiya 
A, Masuda M, Takasu N, Nakamura S, Morishima Y, Seto M. Identification 
of subtype-specific genomic alterations in aggressive adult T-cell leuke-
mia/lymphoma. Blood. 2006;107:4500–7.
 7. Vanura K, Vrsalovic MM, Le T, Marculescu R, Kusec R, Jager U, Nadel B. 
V(D)J targeting mistakes occur at low frequency in acute lymphoblastic 
leukemia. Genes Chromosomes Cancer. 2009;48:725–36.
 8. Lin C, Zheng HT, Wang C, Yang LJ, Chen SH, Li B, Zhou YQ, Tan H, Li YQ. 
Mutations increased overexpression of Notch1 in T-cell acute lympho-
blastic leukemia. Cancer Cell Int. 2012;12:13.
 9. Patel B, Kang Y, Cui K, Litt M, Riberio MS, Deng C, Salz T, Casada S, Fu X, 
Qiu Y, Zhao K, Huang S. Aberrant TAL1 activation is mediated by an inter-
chromosomal interaction in human T-cell acute lymphoblastic leukemia. 
Leukemia. 2014;28:349–61.
 10. Huang X, Du X, Li YQ. The role of BCL11B in hematological malignancy. 
Exp Hematol Oncol. 2012;1:22.
 11. Liu P, Keller JR, Ortiz M, Tessarollo L, Rachel RA, Nakamura T, Jenkins NA, 
Copeland NG. Bcl11a is essential for normal lymphoid development. Nat 
Immunol. 2003;4:525–32.
 12. Przybylski GK, Dik WA, Wanzeck J, Grabarczyk P, Majunke S, Martin-Subero 
JI, Siebert R, Dölken G, Ludwig WD, Verhaaf B, van Dongen JJ, Schmidt CA, 
Langerak AW. Disruption of the BCL11B gene through inv 14 q11.2q32.31 
results in the expression of BCL11B-TRDC fusion transcripts and is 
associated with the absence of wild-type BCL11B transcripts in T- ALL. 
Leukemia. 2005;19:201–8.
 13. Karlsson A, Nordigården A, Jönsson JI, Söderkvist P. Bcl11b mutations 
identified in murine lymphomas increase the proliferation rate of hemat-
opoietic progenitor cells. BMC Cancer. 2007;7:195.
 14. Strehl S, Konig M, Spath K. Juxtaposition of the BCL11B gene to a novel 
region at 17q by a t (14; 17) (q32; Q21) in childhood T-Cell lymphoblastic 
lymphoma [abstract]. Blood. 2007;110:101B.
 15. Su XY, Della-Valle V, Andre-Schmutz I, Lemercier C, Radford-Weiss I, Bal-
lerini P, Lessard M, Lafage-Pochitaloff M, Mugneret F, Berger R, Romana 
SP, Bernard OA, Penard-Lacronique V. HOX11L2/TLX3 is transcriptionally 
activated through T-cell regulatory elements downstream of BCL11B as a 
result of the t (5; 14) (q35; q32). Blood. 2006;108:4198–201.
 16. Huang X, Chen S, Yang LJ, Chen SH, Zhou YB, Schmidt CA, Li YQ. Effects 
of down-regulating BCL11B expression on the proliferation, apoptosis 
and global gene expression profiling of Molt-4 cells [abstract]. Blood. 
2009;114:4505.
 17. Grabarczyk P, Przybylski GK, Depke M, Völker U, Bahr J, Assmus K, Bröker 
BM, Walther R, Schmidt CA. Inhibition of BCL11B expression leads to 
apoptosis of malignant but not normal mature T cells. Oncogene. 
2007;26:3797–810.
 18. Huang X, Chen S, Shen Q, Chen SH, Yang LJ, Grabarczyk P, Przybylski GK, 
Schmidt CA, Li YQ. Down regulation of BCL11B expression inhibits prolif-
eration and induces apoptosis in malignant T cells by BCL11B-935-siRNA. 
Hematology. 2011;16:236–42.
 19. Shen Q, Huang X, Chen S, Yang L, Shen SH, Li B, Wu X, Grabarczyk P, Przyb-
ylski GK, Schmidt CA, Li Y. BCL11B suppression does not influence CD34+ 
cell differentiation and proliferation. Hematology. 2012;17(6):329–33.
 20. Manuel A, Beaupain D, Romeo PH, Raich N. Molecular characterization 
of a novel gene family (PHTF) conserved from Drosophila to mammals. 
Genomics. 2000;64(2):216–20.
 21. Raich N, Mattei MG, Romeo PH, Beaupain D. PHTF, a novel atypical home-
obox gene on chromosome 1p13, is evolutionarily conserved. Genomics. 
1999;59:108–9.
 22. Oyhenart J, Benichou S, Raich N. Putative homeodomain transcription 
factor 1 interacts with the feminization factor homolog fem1b in male 
germ cells. Biol Reprod. 2005;72:780–7.
 23. Subauste MC, Sansom OJ, Porecha N, Raich N, Du L, Maher JF. Fem1b, a 
proapoptotic protein, mediates proteasome inhibitor-induced apoptosis 
of human colon cancer cells. Mol Carcinog. 2010;49:105–13.
 24. Huang X, Chen SH, Shen Q, Yang LJ, Li B, Zhong LY, Geng SX, Du X, Li YQ. 
Analysis of the expression pattern of the BCL11B gene and its relatives 
in patients with T-cell acute lymphoblastic leukemia. J Hematol Oncol. 
2010;3:44.
 25. Luo XD, Tan H, Zhou YQ, Xiao TT, Wang CY, Li YQ. Notch1 signaling 
is involved in regulating Foxp3 expression in T-ALL. Cancer Cell Int. 
2013;13:34.
 26. Bartram I, Gökbuget N, Schlee C, Heesch S, Fransecky L, Schwartz S, 
Stuhlmann R, Schäfer-Eckhart K, Starck M, Reichle A, Hoelzer D, Baldus 
CD, Neumann M. Low expression of T-cell transcription factor BCL11b 
predicts inferior survival in adult standard risk T-cell acute lymphoblastic 
leukemia Patients. J Hematol Oncol. 2014;7:51.
 27. Lyu X, Xin Y, Mi R, Ding J, Wang X, et al. Overexpression of Wilms tumor 1 
gene as a negative prognostic indicator in acute myeloid leukemia. PLoS 
One. 2014;9(3):e92470. doi:10.1371/journal.pone.0092470.
 28. Chan SL, Tan KO, Zhang L, Yee KS, Ronca F, Chan MY, Yu VC. F1Aalpha, 
a death receptor-binding protein homologous to the Caenorhabditis 
elegans sex-determining protein, FEM-1, is a caspase substrate that medi-
ates apoptosis. J Biol Chem. 1999;274:32461–8.
 29. Subauste MC, Ventura-Holman T, Du L, Subauste JS, Chan SL, Yu VC, 
Maher JF. RACK1 downregulates levels of the pro-apoptotic protein 
Fem1b in apoptosis-resistant colon cancer cells. Cancer Biol Ther. 
2009;8(23):2297–305.
 30. Gu S, Zhao Y, Guo J, Xu F, Fei C, Zhang X, Xiao C, Chang C, Li X. High 
expression of APAF-1 elevates erythroid apoptosis in iron overload 
myelodysplastic syndrome. Tumour Biol. 2014;35(3):2211–8.
 31. Zermati Y, Mouhamad S, Stergiou L, Besse B, Galluzzi L, Boehrer S, Pauleau 
AL, Rosselli F, D’Amelio M, Amendola R, Castedo M, Hengartner M, Soria 
JC, Cecconi F, Kroemer G. Nonapoptotic role for Apaf-1 in the DNA dam-
age checkpoint. Mol Cell. 2007;28(4):624–37.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
